IFXY yields 666666.67% · ABBV yields 3.06%● Live data
📍 IFXY pulled ahead of the other in Year 1
Combined, IFXY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IFXY + ABBV for your $10,000?
Infrax Systems, Inc. provides a series of interrelated operational management, communications, and electric power grid security related products and services that enable a unified solution for communications and applications management of the smart electric power grid. The company offers Secure Intelligent Energy Platform that offers utilities the ability to communicate with devices connected to the power grid. It also provides communication devices, including Secure Network Interface Card that resides in the utility power meter to encrypt and transport the data, such as usage, voltage, current, etc.; and collectors, concentrators, and repeaters. In addition, it offers GridMesh software that allows its hardware devices to securely join the network and communicate with each other; Utility Max (UMAX) and UMAX+ wireless solutions for electric power utilities and telephone carriers to set up a point-to-point or point-to-multipoint Ethernet links; and Grid Intrusion Management systems. Further, the company provides distribution automation solution for two-way communications from distribution devices along the power grid to the back office or substations; managed services and customer support, such as network design, deployment support, and program management; and professional services comprising engineering, construction, and project management services to the smaller utilities. Additionally, it offers asset tracker solution for the inventory management of utility smart electric power grid assets, including meters, collectors, and concentrators, as well as substation and field deployable assets. The company was formerly known as OptiCon Systems, Inc. and changed its name to Infrax Systems, Inc. in January 2010. Infrax Systems, Inc. was founded in 2004 and is based in St. Petersburg, Florida.
Full IFXY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.